- Home
- NBIX vs PSO Comparison
NBIX vs PSO Comparison
Compare NBIX & PSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- PSO
- Stock Information
- Founded
- NBIX 1992
- PSO 1844
- Country
- NBIX United States
- PSO United Kingdom
- Employees
- NBIX N/A
- PSO N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- PSO Books
- Sector
- NBIX Health Care
- PSO Consumer Discretionary
- Exchange
- NBIX Nasdaq
- PSO Nasdaq
- Market Cap
- NBIX 11.6B
- PSO 11.2B
- IPO Year
- NBIX 1996
- PSO 2000
- Fundamental
- Price
- NBIX $120.69
- PSO $17.05
- Analyst Decision
- NBIX Buy
- PSO
- Analyst Count
- NBIX 21
- PSO 0
- Target Price
- NBIX $168.35
- PSO N/A
- AVG Volume (30 Days)
- NBIX 1.6M
- PSO 326.3K
- Earning Date
- NBIX 02-06-2025
- PSO 01-01-0001
- Dividend Yield
- NBIX N/A
- PSO 1.72%
- EPS Growth
- NBIX 33.20
- PSO 23.43
- EPS
- NBIX 3.29
- PSO 0.63
- Revenue
- NBIX $2,355,300,000.00
- PSO $4,485,194,688.00
- Revenue This Year
- NBIX $16.29
- PSO N/A
- Revenue Next Year
- NBIX $16.90
- PSO $5.65
- P/E Ratio
- NBIX $36.68
- PSO $25.86
- Revenue Growth
- NBIX 24.81
- PSO N/A
- 52 Week Low
- NBIX $110.95
- PSO $11.78
- 52 Week High
- NBIX $157.98
- PSO $17.25
- Technical
- Relative Strength Index (RSI)
- NBIX 35.76
- PSO 62.25
- Support Level
- NBIX $113.00
- PSO $16.30
- Resistance Level
- NBIX $118.61
- PSO $17.25
- Average True Range (ATR)
- NBIX 4.28
- PSO 0.17
- MACD
- NBIX -2.22
- PSO 0.03
- Stochastic Oscillator
- NBIX 18.81
- PSO 78.95
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About PSO Pearson Plc
U.K.-listed Pearson is the world's largest educational provider. The company has been disposing of noncore businesses such as the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider. While Pearson's primary activity centres on higher-level education, the firm also has significant operations in providing clinical assessments, professional certification and testing.